The European Parkinson’s Disease Association (EPDA) is the only European umbrella organisation for Parkinson’s disease. A non-political, non-religious, and non-profit making organisation, it represents 45 member organisations and is the advocate for the rights and needs of over 1.2 million people1 with Parkinson’s and their families. EPDA’s vision is to enable a full life with Parkinson’s whilst supporting the search for a cure and seeks to achieve this by raising awareness and reducing inequalities in the treatment and management of Parkinson’s disease across Europe.
The EPDA relies on partnership with external organisations for the continuation of its operations. In order to ensure its independence, the EPDA does not accept donations that are dependent on policies set by others. The Administration Board exercises care that funding does not condition its priority setting, the vision, messages, or any other activities of the organisation, thereby ensuring the independence of the EPDA to carry out its strategic direction.
Our partners are companies and organisations of high standing and reputation, all of whom reinforce the EPDA’s overall strategic direction, and help support the integrity of the organisation. Our partnership is established on the basis of shared interest, transparency, trust, and mutual benefit.
Partners do not represent the EPDA as an endorser of any specific product or service, nor does any partnership imply the EPDA’s endorsement of a corporation, its products or its services.
The EPDA would like to thank all our partners and sponsors for their continued support and partnership of the EPDA work programme and look forward to working closely with them to improve the quality of life of people with Parkinson's and their families throughout Europe
Use of the EPDA logo
The EPDA logo is a registered trademark. The Trade Mark
provides uniform protection across member states of the European Union
(EU).
Use of the EPDA logo on any external publications or promotional material, has to be agreed and is subject to a € 6,000 fee.
How is the EPDA Funded?
Click here to find out.
Reference
-
P. Andlin-Sobocki et al, European Journal of Neurology 12 (Suppl 1) June 2005